Scientific publications on systematic review and meta-analysis from Chinese authors: a 10-year survey of the English literature

doi:10.1007/s11684-012-0181-y

Front Med

0, Vol.

Issue () : 94-99 https://doi.org/10.1007/s11684-012-0181-y

RESEARCH ARTICLE

Scientific publications on systematic review and meta-analysis from Chinese authors: a 10-year survey of the English literature

Zhiping Yang(

), Qiong Wu, Kaichun Wu, Daiming Fan

Evidence-Based Medicine Group, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an 710032, China

Download: PDF(221 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Systematic reviews and meta-analyses are playing an increasingly important role in clinical research and practice. This study aimed to measure the scientific production of systematic review and meta-analysis from the three major regions of China: the Mainland (ML), Hong Kong (HK), and Taiwan (TW). English articles on systematic review and meta-analysis from ML, HK, and TW from 2001 to 2010 were retrieved from the PubMed database. The total number of articles, impact factors (IF), and articles published in high-impact journals were conducted for quantity and quality comparisons among the three regions. There were 1 587 published articles from ML (1 292), HK (203), and TW (92) during the past ten years. The annual total numbers of articles in the three regions increased significantly from 2001 to 2010 (from 13 to 677). The number of articles from ML has exceeded that from TW since 2001, and surpassed that from HK in 2003. The accumulated IF of articles from ML (3 488.24) was higher than those from HK (493.16) and TW (216.39). HK had the highest average IF of 3.31, followed by ML of 2.90 and TW of 2.85. Researchers from HK published a larger proportion of papers in high-impact journals than those from ML and TW. The Cochrane Database of Systematic Reviews was the most popular journal in China. Chinese authors have been very active to enhance the systematic review and meta-analysis research over the past ten years, especially in ML. The gap between ML and the other two regions has been narrowed. But there is still considerable room for Chinese authors to improve their studies on systematic review and meta-analysis.

Keywords systematic review meta-analysis China Chinese impact factor

Corresponding Author(s): Yang Zhiping,Email:zpyang@fmmu.edu.cn

Issue Date: 05 March 2012

Cite this article:

Zhiping Yang,Qiong Wu,Kaichun Wu, et al. Scientific publications on systematic review and meta-analysis from Chinese authors: a 10-year survey of the English literature[J]. Front Med, 0, (): 94-99.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-012-0181-y
https://academic.hep.com.cn/fmd/EN/Y0/V/I/94

Fig.1 The numbers of articles from China, USA, England of UK, Germany, France, and Japan from 2001 to 2010.

Fig.2 The numbers of articles from the Mainland, Hong Kong, and Taiwan of China from 2001 to 2010.

Fig.3 Productivity of the institution where research had been carried out in the three regions of China.

Tab.1 The accumulated and average impact factors (IF) of articles from the Mainland (ML), Hong Kong (HK), and Taiwan (TW) of China

Fig.4 The distribution of articles from the three Chinese regions during the past ten years in relation to the impact factor.

Fig.5 The distributing proportions of articles from the three Chinese regions during the past ten years in the four impact factor intervals.

Tab.2 The three most popular English journals for authors from the Mainland (ML), Hong Kong (HK), and Taiwan (TW) of China

Tab.3 The top three English journals of high impact factors (IF) for authors from the Mainland (ML), Hong Kong (HK), and Taiwan (TW) of China

1	Liberati A, Altman DG, Tetzlaff J, Mulrow C, G?tzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151(4): W65-94 pmid:19622512
2	Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol 1995; 48(1): 167-171 doi: 10.1016/0895-4356(94)00172-M pmid:7853043
3	Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG. Epidemiology and reporting characteristics of systematic reviews. PLoS Med 2007; 4(3): e78 doi: 10.1371/journal.pmed.0040078 pmid:17388659
4	Shojania KG, Bero LA. Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy. Eff Clin Pract 2001; 4(4): 157-162 pmid:11525102
5	Top 20 countries in all fields, 2000-August31, 2010. http://sciencewatch.com/dr/cou/2010/10decAll(Access on April 15, 2011)
6	Robinson KA, Goodman SN. A systematic examination of the citation of prior research in reports of randomized, controlled trials. Ann Intern Med 2011; 154(1): 50-55 pmid:21200038
7	Ragghianti CP, Martínez R, Martins J, Gallo JE. Comparative study of scientific publications in Ophthalmology and Visual Sciences in Argentina, Brazil, Chile, Paraguay and Uruguay (1995-2004). Arq Bras Oftalmol 2006; 69(5): 719-723 doi: 10.1590/S0004-27492006000500019 pmid:17187142
8	Wang J. Evidence-based medicine in China. Lancet 2010; 375(9714): 532-533 doi: 10.1016/S0140-6736(09)62131-0 pmid:20159275
9	Carter MJ. Evidence-based medicine: an overview of key concepts. Ostomy Wound Manage 2010; 56(4): 68-85 pmid:20424294
10	Andersen J, Belmont J, Cho CT. Journal impact factor in the era of expanding literature. J Microbiol Immunol Infect 2006; 39(6): 436-443 pmid:17164944
11	Oh HC, Lim JF. Is the journal impact factor a valid indicator of scientific value? Singapore Med J 2009; 50(8): 749-751 pmid:19710968
12	About The Cochrane Library. http://www.thecochranelibrary.com/view/0/AboutTheCochraneLibrary.html#CDSR (Access on April16, 2011)
13	Chinese Cochrane Centre (in Chinese).http://www.hxyx.com/cochrane_new (Access on April16, 2011)
14	Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB; the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283(15): 2008-2012 doi: 10.1001/jama.283.15.2008 pmid:10789670

[1]	Heling Bao, Yuanyuan Huang, Yi Sun, Yunli Chen, Yan Luo, Liping Yan, Sailimai Man, Canqing Yu, Jun Lv, Meili Ge, Linhong Wang, Liming Li, Bo Wang, Hui Liu, Xiaoxi Liu. Prevalence of anemia of varying severity, geographic variations, and association with metabolic factors among women of reproductive age in China: a nationwide, population-based study[J]. Front. Med., 2024, 18(5): 850-861.
[2]	Xuan Zhang, Han Li, Hanzhi Tan, Nana Wang, Chung Wah Cheng, Juan Wang, Dongni Shi, Lin Zhang, Yumeng Liu, Yao Wang, Shufeng Luo, Yaxin Lin, Lihan Hu, Xuanqi Zhang, Ji Li, Fei Han, Ping Wang, Aiping Lyu, Zhaoxiang Bian. Suboptimal reporting of randomized controlled trials on non-pharmacological therapies in Chinese medicine[J]. Front. Med., 2024, 18(5): 798-813.
[3]	Yingbin Wang, Yu Zhang, Guihua Yao, Hong Tang, Lixin Chen, Lixue Yin, Tiangang Zhu, Jianjun Yuan, Wei Han, Jun Yang, Xianhong Shu, Ya Yang, Yulin Wei, Yanli Guo, Weidong Ren, Dongmei Gao, Guilin Lu, Ji Wu, Hongning Yin, Yuming Mu, Jiawei Tian, Lijun Yuan, Xiaojing Ma, Hongyan Dai, Yunchuan Ding, Mingyan Ding, Qing Zhou, Hao Wang, Di Xu, Mei Zhang, Yun Zhang. Echocardiographic Measurements in Normal Chinese Adults (EMINCA) II focusing on left ventricular and left atrial size and function by three-dimensional echocardiography[J]. Front. Med., 2024, 18(4): 649-663.
[4]	Linhua Zhao, Chuanxi Tian, Yingying Yang, Huifang Guan, Yu Wei, Yuxin Zhang, Xiaomin Kang, Ling Zhou, Qingwei Li, Jing Ma, Li Wan, Yujiao Zheng, Xiaolin Tong. Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19[J]. Front. Med., 2023, 17(6): 1014-1029.
[5]	Jun Feng, Li Zhang, Zhigui Xia, Shuisen Zhou, Ning Xiao, Xiao-Nong Zhou. Achievements of the national malaria control and elimination program in the People’s Republic of China: the Atlas of Malaria Transmission in China[J]. Front. Med., 2023, 17(1): 85-92.
[6]	Jiansheng Li, Hulei Zhao, Yang Xie, Jieya Li, Qingwei Li, Xuexin Chen, Weiyu Zhang. Clinical efficacy of comprehensive therapy based on traditional Chinese medicine patterns on patients with pneumoconiosis: a pilot double-blind, randomized, and placebo-controlled study[J]. Front. Med., 2022, 16(5): 736-744.
[7]	Rongrong Wang, Liwei Sun, Xiaerbati Habulieti, Jiawei Liu, Kexin Guo, Xueting Yang, Donglai Ma, Xue Zhang. *Novel variants in LAMA3* and COL7A1 and recurrent variant in KRT5 underlying epidermolysis bullosa in five Chinese families**[J]. Front. Med., 2022, 16(5): 808-814.
[8]	Kaili Yang, Jiarui Li, Lin Zhao, Zhao Sun, Chunmei Bai. Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors[J]. Front. Med., 2022, 16(5): 773-783.
[9]	Liang Dai, Jingjuan Xu, Baocheng Liu, Yanqi Dang, Ruirui Wang, Lijie Zhuang, Dong Li, Lulu Jiao, Jianying Wang, Lei Zhang, Linda L.D. Zhong, Wenjun Zhou, Guang Ji. Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach[J]. Front. Med., 2022, 16(5): 745-759.
[10]	Jianhai Yin, Mei Li, He Yan, Shuisen Zhou, Zhigui Xia. Laboratory diagnosis for malaria in the elimination phase in China: efforts and challenges[J]. Front. Med., 2022, 16(1): 10-16.
[11]	Fang Huang, Yanwen Cui, He Yan, Hui Liu, Xiangrui Guo, Guangze Wang, Shuisen Zhou, Zhigui Xia. *Prevalence of antifolate drug resistance markers in Plasmodium vivax* in China**[J]. Front. Med., 2022, 16(1): 83-92.
[12]	Qiaoli Shi, Fei Xia, Qixin Wang, Fulong Liao, Qiuyan Guo, Chengchao Xu, Jigang Wang. Discovery and repurposing of artemisinin[J]. Front. Med., 2022, 16(1): 1-9.
[13]	Wenjun Tu, Feng Yan, Baohua Chao, Xunming Ji, Longde Wang. Status of hyperhomocysteinemia in China: results from the China Stroke High-risk Population Screening Program, 2018[J]. Front. Med., 2021, 15(6): 903-912.
[14]	Yu Wang, Lan Li, Yuanjiang Pan, Yu He, Zuhua Chen, Yunhao Xun, Yuhan Xu, Yilei Guo, Jiehong Yang, Jianchun Guo, Haitong Wan. Comparison of the clinical features and therapeutics of COVID-19 in cardio-cerebrovascular disease (CCVD) and non-CCVD patients[J]. Front. Med., 2021, 15(4): 629-637.
[15]	Ling Dai, Xiang Gao, Zhihua Ye, Hanmin Li, Xin Yao, Dingbo Lu, Na Wu. The “Traditional Chinese medicine regulating liver regeneration” treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data[J]. Front. Med., 2021, 15(3): 495-505.

Viewed

Full text

Abstract

Cited

Shared

Discussed